$CVRS News

Last published 5mo ago

5mo agoSYK CVRSBioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech EcosystemBusiness WireThree companies with strong roots in the state are revolutionizing the treatment of cardiovascular disease through hydraulic lithotripsy technology BioStar Capital, a venture capital firm focused on transformative
5y agoBEAT GMED GTHX HOLX+10IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERSGlobeNewswireMARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting
7y agoCVRSCorindus Joins Russell 3000® IndexBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1.
7y agoCVRSCorindus Reports Fourth Quarter and Full Year 2018 ResultsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its fourth quarter and year ended December 31, 2018.
7y agoCVRSCorindus Vascular Robotics Announces Additional Closing of Private PlacementBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced the execution of an additional closing of the private placement previously announced on February 26, 2019. In the additional closing, existing investors with preemptive rights purchased an aggregate of 3,512,124 s ...
7y agoCVRSCorindus to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release fourth quarter and full year 2018 financial and business results on Tuesday, March 12, 2019 after the close of the U.S. financial markets.
7y agoCVRSCorindus to Present at 39th Annual Cowen Health Care Conference on March 13, 2019Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 39th Annual Cowen Health Care Conference as follows:
7y agoCVRSCorindus Vascular Robotics Announces Closing of Private Placement for $15 MillionBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at a purchase price of $1.3796 pe ...
7y agoCVRSCorindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic SystemBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention. CorPath GRX, the second generation robotic platform, received FDA cle ...
7y agoCVRSCorindus’ Technology Successfully Used in World’s First-in-Human Telerobotic Coronary InterventionBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announces that its CorPath technology was used to conduct the first-in-human (FIH) Telerobotic Intervention Study, December 4 and 5, 2018, in India. This study represents the world’s first percutaneous coronary intervention (PCI) conducted from a remote locat ...
8y agoCVRSCorindus Vascular Robotics, Inc. (CVRS) CEO Mark Toland on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoCVRSCorindus to Present at Upcoming 2018 Healthcare ConferencesBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that management will present at two investor conferences in November as follows:
8y agoCVRSCorindus Reports Third Quarter 2018 ResultsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today reported financial results for its third quarter ended September 30, 2018.
8y agoCVRSCorindus to Report Third Quarter Financial Results on November 6, 2018Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the third quarter of 2018 on Tuesday, November 6, 2018 after the close of the U.S. financial markets.
8y agoCVRSCorindus Technology Successfully used in Multiple Live Complex Robotic-Assisted Coronary Interventions at Transcatheter Cardiovascular Therapeutics 2018Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that its CorPath GRX System was used for multiple complex robotic-assisted percutaneous coronary interventions (PCI) at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference. In the first case at University of Washington M ...
8y agoCVRSCorindus Announces First Live Transmission of Remote Robotic Demonstration Performed at Transcatheter Cardiovascular Therapeutics 2018 ConferenceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced the first live transmission of a remote interventional procedure using the company’s CorPath® platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego, CA on September 22, 2018. The remote interventional ...
8y agoCVRSCorindus to Present at Ladenburg Thalmann 2018 Healthcare ConferenceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference as follows:
8y agoCVRSCorindus to Feature the CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2018 ConferenceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, will feature its CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference, September 21 – 25, in San Diego, CA. Corindus' CorPath GRX is the first FDA-cleared medical device for robotic-assisted vascular interventions. The co ...
8y agoCVRSCorindus to Present at 13th Annual Wells Fargo Securities Healthcare ConferenceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 13th Annual Wells Fargo Securities Healthcare Conference. Details for the presentation include:
8y agoCVRSCorindus Reports Second Quarter 2018 ResultsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today reported financial results for its second quarter ended June 30, 2018.
8y agoCVRSCorindus to Showcase CorPath GRX® System for Peripheral Vascular Interventions at the 2018 Amputation Prevention SymposiumBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that the CorPath GRX System will be showcased for peripheral applications at the 2018 Amputation Prevention Symposium in Chicago, IL. Jihad Mustapha, M.D., Interventional Cardiologist and AMP course director, will moderate an educational sessi ...
8y agoCVRSCorindus to Present at Canaccord Genuity 38th Annual Growth ConferenceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.
8y agoCVRSCorindus to Report Second Quarter Financial Results on August 7, 2018Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2018 after the close of trading on Tuesday, August 7, 2018.
8y agoCVRSCorindus Announces Significant Progress in the Development of Remote Vascular Robotic Technology with the CorPath GRX® SystemBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Ryan Madder, M.D., an interventional cardiologist at Spectrum Health, has successfully completed a remote percutaneous coronary intervention (PCI) in a porcine model using the CorPath GRX System from a location greater than 100 miles from ...
8y agoCVRSCorindus Names Aquilla S. Turk, D.O. as Chief Medical Officer, NeuroendovascularBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Aquilla "Quill" Turk, D.O. has joined the company as Chief Medical Officer, Neuroendovascular. Dr. Turk is a practicing physician at the Medical University of South Carolina where he serves as Director of the Stroke and Cerebrovascular Pro ...
8y agoCVRSCorindus Promotes Doug Teany to Chief Operating OfficerBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has appointed Douglas Teany, currently the company’s Senior Vice President of R&D and Operations, to Chief Operating Officer, effective immediately.
8y agoCVRSCorindus Announces Pharmaceutical and Medical Device Agency (PMDA) Approval of CorPath GRX System in JapanBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received Pharmaceutical and Medical Device Agency (PMDA) Approval for commercialization of its CorPath® GRX System in Japan. Japan is one of the largest markets in the world for percutaneous coronary interventions (PCI) with approximat ...
8y agoCVRSCorindus Reports First Quarter 2018 ResultsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its first quarter ended March 31, 2018.
8y agoCVRSCorindus to Report First Quarter Financial Results on May 8, 2018Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the first quarter of 2018 after the close of trading on Tuesday, May 8, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss ...
8y agoCVRSCorindus Presents "Optimizing Care with CorPath GRX: Hot Topics in Robotic Interventions" at SCAI 2018 Dinner Symposium on April 26Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will sponsor a dinner event during the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions at the Manchester Grand Hyatt in San Diego, California. Vascular robotics will be featured throughout the c ...
8y agoCVRSCorindus Announces $25 Million Private Placement of Series A Convertible Preferred Shares and WarrantsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has entered into definitive agreements to issue newly-designated Series A Convertible Preferred Stock to a select group of existing investors including Hudson Executive Capital and BioStar Ventures, and new investors, for gross proceed ...
8y agoCVRSCorindus Reports Fourth Quarter and Full Year 2017 ResultsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its fourth quarter and year ended December 31, 2017.
8y agoCVRSCorindus to Report Fourth Quarter and Full Year 2017 Financial Results on March 14, 2018Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the fourth quarter of 2017 after the close of trading on Wednesday, March 14, 2018. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to di ...
8y agoCVRSJames R. Tobin Joins Corindus Board of DirectorsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that James (Jim) Tobin has been appointed to its Board of Directors, effective immediately.
8y agoCVRSCorindus to Present at Cowen Health Care ConferenceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Health Care Conference hosted by Cowen in Boston, MA.
8y agoCVRSCorindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX PlatformBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform.
8y agoCVRSDelray Beach Medical Center Performs First Robotic-Assisted Peripheral Vascular Intervention Using Corindus CorPath® GRX System Following FDA ClearanceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the successful completion of the first robotic-assisted peripheral vascular intervention procedure using the recently FDA-cleared CorPath GRX System. The procedure was performed by Joseph Ricotta, M.D., Medical Director of Vascular Surgery and ...
8y agoCVRSCorindus Receives FDA Clearance for CorPath® GRX System in Peripheral Vascular InterventionsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic prec ...
8y agoCVRSCorindus to Co-Sponsor Courses at Multiple Leading Healthcare Institutions on Value-based Interventional Procedural TrainingBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions. The course series entitled "Complex Radial Interventions on Robotic and Ma ...
8y agoCVRSCorindus Announces Preliminary Fourth Quarter and Full Year 2017 RevenueBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported preliminary revenue results for the fourth quarter and year ended December 31, 2017.
8y agoCVRSCorindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary Interventions Remote Treatment CapabilitiesBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it is working with Mayo Clinic in a preclinical study about use of telestenting. Telestenting, or the remote robotic treatment for percutaneous coronary intervention (PCI), may enable physicians to conduct procedures from virtually any lo ...
8y agoCVRSCorindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc.(NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the first commercial installation of a CorPath GRX System outside of the United States. The system was purchased by the Apex Heart Institute in Ahmedabad, India, a state of the art cardiology center. Corindus will partner with Apex Heart Instit ...
8y agoCVRSCorindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for PhysiciansBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath® GRX Systems. ...
9y agoCVRSCorindus Vascular Robotics Reports Third Quarter 2017 ResultsBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for the quarter ended September 30, 2017.
9y agoCVRSCorindus to Present at Upcoming Investor ConferencesBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced the Company will be participating in two upcoming investor conferences.
9y agoCVRSCorindus to Feature CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2017 ConferenceBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it will be participating in the Transcatheter Cardiovascular Therapeutics (TCT) 2017 Conference to be held October 29 – November 2 in Denver, CO. Robotic-assisted percutaneous coronary intervention (PCI) will be featured throughout the con ...
9y agoCVRSCorindus Vascular Robotics to Report Third Quarter 2017 Financial Results on November 7, 2017Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2017 after the close of trading on Tuesday, November 7, 2017. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to di ...
9y agoCVRSCorindus Evaluates Incorporating HeartFlow Technology with CorPath GRX SystemBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will incorporate the HeartFlow® FFRct Analysis in a case series of robotic-assisted percutaneous coronary intervention (PCI) procedures with the CorPath® GRX System to evaluate the feasibility and utility of clinical decision support.
9y agoCVRSCorindus Announces Opening of First International Robotic Training CenterBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today the opening of the first international CorPath GRX Robotic Center in Tokyo, Japan. Earlier this year, Corindus partnered with Japan Medicalnext Co., Ltd., a wholly-owned entity of MC Healthcare, Inc. (subsidiary of Mitsubishi Corporation), to ...
9y agoCVRSCorindus Announces First Patient Enrolled in PRECISION GRX RegistryBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced first patient enrollment in the PRECISION GRX Registry, a post-market study to continue market surveillance of the Company's second generation CorPath GRX System.